Open Access

Curcumin slows osteoarthritis progression and relieves osteoarthritis-associated pain symptoms in a post-traumatic osteoarthritis mouse model

  • Zhuo Zhang1, 2, 3,
  • Daniel J. Leong1, 2,
  • Lin Xu1, 2,
  • Zhiyong He1, 2,
  • Angela Wang1, 2,
  • Mahantesh Navati4, 5,
  • Sun J. Kim1,
  • David M. Hirsh1,
  • John A. Hardin1,
  • Neil J. Cobelli1,
  • Joel M. Friedman4, 5 and
  • Hui B. Sun1, 2Email author
Contributed equally
Arthritis Research & Therapy201618:128

https://doi.org/10.1186/s13075-016-1025-y

Received: 4 February 2016

Accepted: 18 May 2016

Published: 3 June 2016

Abstract

Background

Curcumin has been shown to have chondroprotective potential in vitro. However, its effect on disease and symptom modification in osteoarthritis (OA) is largely unknown. This study aimed to determine whether curcumin could slow progression of OA and relieve OA-related pain in a mouse model of destabilization of the medial meniscus (DMM).

Methods

Expression of selected cartilage degradative-associated genes was evaluated in human primary chondrocytes treated with curcumin and curcumin nanoparticles and assayed by real-time PCR. The mice subjected to DMM surgery were orally administered curcumin or topically administered curcumin nanoparticles for 8 weeks. Cartilage integrity was evaluated by Safranin O staining and Osteoarthritis Research Society International (OARSI) score, and by immunohistochemical staining of cleaved aggrecan and type II collagen, and levels of matrix metalloproteinase (MMP)-13 and ADAMTS5. Synovitis and subchondral bone thickness were scored based on histologic images. OA-associated pain and symptoms were evaluated by von Frey assay, and locomotor behavior including distance traveled and rearing.

Results

Both curcumin and nanoparticles encapsulating curcumin suppressed mRNA expression of pro-inflammatory mediators IL-1β and TNF-α, MMPs 1, 3, and 13, and aggrecanase ADAMTS5, and upregulated the chondroprotective transcriptional regulator CITED2, in primary cultured chondrocytes in the absence or presence of IL-1β. Oral administration of curcumin significantly reduced OA disease progression, but showed no significant effect on OA pain relief. Curcumin was detected in the infrapatellar fat pad (IPFP) following topical administration of curcumin nanoparticles on the skin of the injured mouse knee. Compared to vehicle-treated controls, topical treatment led to: (1) reduced proteoglycan loss and cartilage erosion and lower OARSI scores, (2) reduced synovitis and subchondral plate thickness, (3) reduced immunochemical staining of type II collagen and aggrecan cleavage epitopes and numbers of chondrocytes positive for MMP-13 and ADAMTS5 in the articular cartilage, and (4) reduced expression of adipokines and pro-inflammatory mediators in the IPFP. In contrast to oral curcumin, topical application of curcumin nanoparticles relieved OA-related pain as indicated by reduced tactile hypersensitivity and improved locomotor behavior.

Conclusion

This study provides the first evidence that curcumin significantly slows OA disease progression and exerts a palliative effect in an OA mouse model.

Keywords

Post-traumatic osteoarthritisCurcuminNutraceuticalsChondroprotectionMMPsADAMTS5

Background

Osteoarthritis (OA) is a progressive and degenerative disease of the articular joints involving the articular cartilage, synovium, and subchondral bone, and is a leading cause of pain and disability in the adult population [1]. Despite the high prevalence of OA, there is currently no cure or effective treatment that halts or reverses disease progression [2]. While current pharmacologic treatments such as analgesics and nonsteroidal anti-inflammatory drugs (NSAIDs) provide symptomatic relief, such as relieving pain, they do not exert a clear clinical effect on OA disease prevention or modification [3]. In most cases, long-term use of these treatments has been associated with substantial gastrointestinal, renal, and cardiovascular side effects [3]. There is a clear and urgent need for new therapeutic strategies that are effective and safe for OA treatment.

Curcumin, the principal curcuminoid and the most active component in turmeric, is a biologically active phytochemical [4, 5]. Evidence from several recent in vitro studies suggests that curcumin may exert a chondroprotective effect through actions such as anti-inflammatory, anti-oxidative stress, and anti-catabolic activity that are critical for mitigating OA disease pathogenesis and symptoms. For example, curcumin has been shown to mitigate the inflammatory process by decreasing synthesis of inflammatory mediators such as interleukin (IL)-1β, tumor necrosis factor (TNF)-α, IL-6, IL-8, prostaglandin E2 (PGE2), and cyclooxygenase-2 (COX-2) [68], inhibit IL-1β-induced extracellular matrix degradation [9] and chondrocyte apoptosis [10, 11], and mitigate the over-production of reactive oxygen and nitrogen species [12, 13]. Moreover, curcumin, by inhibiting the activator protein 1 (AP-1) pathway [14] and nuclear factor kappa B (NF-kB) activation [1416], suppresses the gene expression of a number of matrix metalloproteinases (MMPs), which play critical roles in the breakdown of the cartilage extracellular matrix [7, 1417].

Despite the recent progress, the effect of curcumin on OA disease progression and pain relief is largely unknown. Moon et al. showed that following intraperitoneal injection of curcumin every other day for 2 weeks, expression of TNF-α and IL-1β in the ankle joint, and serum immunoglobulin concentrations in mice with collagen-induced arthritis were downregulated compared with non-curcumin-treated mice [18], suggesting curcumin may be beneficial in rheumatoid arthritis. Furthermore, Colitti et al. found that oral delivery of curcumin in canines with spontaneous OA leads to decreased IL-18 and TNF-α production, and inhibition of the inflammatory transcription factor NF-kB in white blood cells [19]. The study suggests a potential anti-inflammatory effect of curcumin on the joints in OA.

While several studies suggest oral administration of curcumin may exert an effect in relieving OA-related pain [2024], topical application may provide another patient-friendly method of treatment. Importantly, it may increase the bioavailability of curcumin at the disease site for OA treatment. In this study, we aim to determine the efficacies of curcumin through oral delivery and custom-made nanoparticles through topical administration in OA disease and symptom modification using a mouse model of post-traumatic OA.

Methods

Cell culture and curcumin treatment in vitro

All human studies were approved by the Albert Einstein College of Medicine Institutional Review Board. Human primary chondrocytes derived from patients undergoing joint replacement surgery (women aged 58–69 years, n = 3) were cultured in DMEM/F12 with 10 % fetal bovine serum [25]. Prior to curcumin treatment, cells were cultured in the DMEM/F12 with 1 % fetal bovine serum overnight. In some experiments, chondrocytes were incubated with IL-1β (10 ng/ml, Sigma) 30 minutes prior to incubation with curcumin (100 μM, Sigma) or curcumin (100 μM) encapsulated within nanoparticles for 6 hours. Cells were then lysed and RNA isolated for reverse transcription-quantitative polymerase chain reaction (real-time-PCR) [26]. The dose (100 μM) and treatment duration (6 hours) were chosen based on assays for dose-response (0–200 μM) and time course (0–48 hours) of human primary chondrocytes treated with non-encapsulated curcumin (Additional file 1: Figure S1).

Preparation of curcumin nanoparticles

Curcumin nanoparticles were prepared using a variation of a nanoparticle platform that was developed for topical and systemic delivery of nitric oxide [2729] in three steps as follows [30]: (1) hydrolysis of tetra-methyl-orthosilicate (TMOS). Hydrolyzed TMOS is prepared by sonicating at ice temperature, a mixture of 3 ml TMOS and 600 μl 1 mM HCl in a small glass bottle with rubber stopper. Upon sonication the initial biphasic solution turns into a monophasic solution. The monophasic solution is stored at 4 °C for an hour to help eliminate methanol, a byproduct of TMOS hydrolysis (residual methanol is further eliminated during the lyophilization process); (2) polymerization. The following ingredients are added sequentially to a 50-ml conical tube, which is inverted (to facilitate mixing) after each addition of an ingredient: 24 ml of PBS 50 mM pH 7.5, 1.5 ml PEG 400, 1.5 ml chitosan (5 mg/ml) at pH 6 in acetic acid, 4 ml of 5 mg/ml curcumin (Sigma) dissolved in dimethyl sulfoxide (DMSO) and finally 3 ml hydrolyzed TMOS. After all the ingredients are mixed a homogeneous gel is formed in approximately 30 minutes; (3) lyophilization and ball-milling. The wet sol-gel containing the curcumin is freeze-dried overnight. The resulting dry course powder is then ball-milled and stored in a sealed vial for subsequent use for the experiments. A very similar version of this platform has been used to treat topical infections and accelerate wound healing [31].

Induction of osteoarthritis in mice and curcumin treatment

All animal studies were approved by the Albert Einstein College of Medicine Institutional Animal Care and Use Committee. Destabilization of the medial meniscus (DMM) was established in adult C57BL/6 male mice (male, 5–6 months of age) by surgically transecting the medial meniscotibial ligament (MMTL) in the right hind limb [32]. Briefly, the joint capsule immediately medial to the patellar tendon was incised, followed by blunt dissection of the infrapatellar fat pad, to provide visualization of the MMTL of the medial meniscus. The MMTL was transected, leading to destabilization of the medial meniscus (DMM). In the sham surgery, the MMTL was visualized but not transected. The joint capsule and skin were closed by suture. Immediately after the DMM surgery, mice were subjected to (1) oral administration of 50 mg/kg curcumin (Sigma) dissolved in corn oil or vehicle (corn oil only) administered via oral gavage (n = 8/group), or (2) topical application of curcumin nanoparticles (0.07 mg of 10 μg curcumin/1 mg nanoparticles) or vehicle control (coconut oil) on the skin, within a 5-mm2 area directly above the DMM-operated knee (n = 5/group), once daily for 8 weeks.

Safranin O staining, OARSI score, and histologic evaluation of synovium and subchondral bone

Animals were sacrificed at 8 weeks following curcumin treatment. The hind limbs were fixed in formalin, decalcified in formic acid, embedded in paraffin, and sectioned for histological and immunohistochemical analysis. afranin O-fast green staining was used to visualize proteoglycans in the articular cartilage. The severity of OA was evaluated in the medial compartment of the knee with at least five sections for each mouse using the Osteoarthritis Research Society International (OARSI) scoring system [33]. The synovial pathology (i.e., synovitis) was analyzed on Safranin O stained sections from which the OARSI scores were obtained. The degree of synovitis was scored using a scoring system that measured the thickness of the synovial lining cell layer on a scale of 0–3 (0 = 1–2 cells, 1 = 2–4 cells, 2 = 4–9 cells and 3 = 10 or more cells) and cellular density in the synovial stroma on a scale of 0–3 (0 = normal cellularity, 1 = slightly increased cellularity, 2 = moderately increased cellularity and 3 = greatly increased cellularity). Synovitis scores obtained from all four quadrants (medial tibia, medial femur, lateral tibia, and lateral femur) for both of the above parameters were averaged separately and then the sum of averages from both parameters was used for analysis (on a scale of 0–6) [34]. The thickness of the medial subchondral bone plate (region between the osteochondral junction and marrow space on the medial side of the tibial plateau, in μm) was measured using AxioVision software using Safranin O stained sections from which the OARSI and synovitis scores were obtained [35].

Immunohistochemical analysis

Sections were incubated overnight at 4 °C with antibodies against cleaved aggrecan (NITEGE, Ibex) and cleaved type II collagen (Col2-3/4 M, Ibex), matrix metalloproteinase (MMP)-13 (Abcam), and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)5 (Abcam) followed by incubation with anti-mouse or anti-rabbit secondary antibody (Biocare Medical) and visualization with 3,3-diaminobenzidine (DAB) chromagen (Vector Laboratories). Negative controls were stained with irrelevant isotype-matched antibodies (Biocare Medical). Immunostaining intensity for type II collagen or aggrecan cleavage epitopes was quantified by determining the “reciprocal intensity” of the stained articular cartilage matrix; briefly, the light intensity value of six random locations within all three zones from the posterior to anterior direction of the femoral and tibial condyles of three sections per mouse was measured using the color picker in Adobe Photoshop [36, 37]. Percentages of positive MMP-13 and ADAMTS5 chondrocytes were determined by counting the number of immunostained cells and dividing by the total number of chondrocytes visualized by a hematoxylin counterstain (Vector Laboratories).

In vivo localization of topically applied curcumin

Curcumin nanoparticles (0.07 mg of 10 μg curcumin/1 mg nanoparticles dissolved in coconut oil) or vehicle control (coconut oil) were topically applied on the right knee of adult C57BL/6 mice (male, 5–6 months). At 3, 6, and 24 hours after treatment (n = 3/group), the animals were sacrificed and the hind limbs were fixed in formalin, decalcified in formic acid, embedded in paraffin and sectioned for histological analysis. Sections (5-μm) were stained with hematoxylin and eosin (H&E), and imaged with confocal microscopy to localize the curcumin particles within the articular joint. In a separate group of animals, mice were sacrificed 3 hours after topical application of curcumin nanoparticles or vehicle control (n = 3/group). The IPFP from the right knee was dissected and flash frozen. RNA was isolated for real-time PCR.

von Frey testing

Mice were acclimated for 30 minutes in individual chambers on top of a wire grid platform prior to von Frey testing. The plantar surface of the hind paw was stimulated with ascending force intensities of von Frey filaments (Stoelting) to determine tactile sensitivity. A positive response was defined as a rapid withdrawal of the hind paw when the stimulus was applied, and the number of positive responses for each stimulus was recorded. Tactile threshold was defined as a withdrawal response in 5 out of 10 trials to a given stimulus intensity [37]. This threshold was calculated once per animal.

Pain and OA-related behavioral tests

As we and others previously described, mice were acclimated to the test room for 30 minutes before open field testing [37, 38]. Mice were placed in the center of individual plexiglass square chambers (45 cm × 45 cm) and allowed to freely explore the chamber for the duration of the 6-minute test session. The movements of the mice were recorded with a video camera. Upon completion of the test, which was performed once per animal, each mouse was returned to its home cage. Two observers blinded to treatment group assignments manually traced mouse movements to calculate the distance (in cm) that the mouse traveled within the cage in 6 minutes (distance traveled), and recorded the number of times each mouse reared (standing on its hind limbs) within 6 minutes (rearing) [38].

Real-time PCR

Total RNA was isolated with an RNeasy kit (Qiagen) and cDNA was synthesized using the iScript Reverse Transcriptase kit (Bio-Rad). SYBR Green real-time PCR (Bio-Rad) was performed in duplicate for each sample to determine relative gene expression using Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a housekeeping control with the 2-ΔΔCt method [26, 37].

Statistical analysis

Results are expressed as mean ± SD. Significance was determined using Student’s t test or one-way analysis of variance (ANOVA) and Tukey’s multiple comparison test with a significance level of p < 0.05 (GraphPad).

Results

Gene expression profile change favors chondroprotection in curcumin-treated human chondrocytes in vitro

We first validated the chondroprotective potential of curcumin by gene expression profile analysis in chondrocytes in vitro. Consistent with previous studies [7, 1417], human primary chondrocytes, in the absence and presence of IL-1β, and treated with curcumin, exhibited significantly reduced mRNA levels of proteolytic enzymes MMP-1, MMP-3, and MMP-13, and pro-inflammatory cytokines IL-1β and TNF-α (p < 0.05) (Fig. 1). Interestingly, as shown for the first time, curcumin significantly reduced expression of aggrecanase ADAMTS5 and increased expression of CITED2 (Cbp/p300 Interacting Transactivator with ED-rich tail 2), MMP-repressing transcriptional regulator (p < 0.05) (Fig. 1). No effects of curcumin on expression of anabolic genes collagen 2a1 and aggrecan were observed (p > 0.05) (Fig. 1).
Fig. 1

Chondrocytes treated with curcumin exhibits a gene expression profile that is favorable for chondroprotection. Human primary chondrocytes treated with curcumin for 6 hours exhibited reduced mRNA levels of matrix metalloproteinase (MMP)-1, MMP-3, MMP-13, a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)5, IL-1β, TNF-α, and increased CITED2 compared to vehicle-treated cells, in the absence (a) and presence (b) of IL-1β, while expression of collagen 2a1 (Col2a1) and aggrecan (Acan) remained unchanged. *P < 0.05, t test, n = 3/group

Oral delivery of curcumin slows disease progression but does not significantly affect OA-related symptoms in mice with DMM

We next determined the efficacy of curcumin on DMM-induced OA through oral administration by evaluating the structural integrity of the articular cartilage using microscopy following Safranin O staining and OARSI evaluation. Eight weeks after DMM, the articular cartilage in the limb with DMM in the vehicle-treated mice exhibited moderate pathological osteoarthritic changes characterized by Safranin O loss, cartilage fibrillation, and cartilage erosion (Fig. 2a), with an OARSI score of 4.0 ± 0.5. (Fig. 2b). In contrast, the cartilage in the limb with DMM in curcumin-treated mice exhibited less Safranin O loss and cartilage fibrillation (Fig. 2a) with a significantly lower OARSI score (2.4 ± 0.42) compared to that in vehicle-treated controls (p < 0.05, Fig. 2b). Curcumin treatment also significantly reduced synovitis (Fig. 2c) and subchondral plate thickness (Fig. 2d) compared to vehicle controls (p < 0.05 for both). However, oral administration of curcumin had no significant effect on mitigating OA-related pain, as evaluated by von Frey testing, distance traveled and hind limb rearing (not shown).
Fig. 2

Oral administration of curcumin slowed progression of post-traumatic osteoarthritis in mice. Mice with destabilization of the medial meniscus (DMM) were treated daily with curcumin (Cur) or vehicle via oral gavage. Mice with DMM treated with curcumin exhibited improved Safranin O staining (a), lower Osteoarthritis Research Society International (OARSI) scores (b), and reduced synovitis (c) and subchondral plate thickness (d) at 8 weeks following surgery, compared to mice with DMM that were treated with vehicle (Veh). *P < 0.05, t test, n = 8/group. Representative histologic images are shown

Curcumin nanoparticles exert an anti-catabolic and anti-inflammatory effect in human chondrocytes in vitro

While oral administration of non-encapsulated curcumin exhibited significant efficacy in slowing the progression of OA, its therapeutic efficacy may be restricted by its relatively poor oral bioavailability [39]. We therefore developed curcumin nanoparticles using a novel polymeric nanoparticle carrier [30]. To test whether nanoparticles encapsulating curcumin affect the chondroprotective potential of curcumin, we compared the gene expression profile in primary cultured human chondrocytes in the absence or presence of IL-1β and treated with curcumin nanoparticles or vehicle control. Curcumin nanoparticles significantly reduced mRNA levels of MMP-1, MMP-3, MMP-13, ADAMTS5, IL-1β and TNF-α, and increased levels of CITED2 chondrocytes compared to the vehicle control (p < 0.05 for all), at a comparable level to that of non-encapsulated curcumin-treated chondrocytes, based on the equivalent concentration of curcumin, in the absence or presence of IL-1β (p > 0.05 for all, Fig. 3). No significant effects of curcumin nanoparticles on expression of collagen 2a1 and aggrecan were observed (p > 0.05) (Fig. 3).
Fig. 3

Curcumin nanoparticles exert anti-catabolic and anti-inflammatory effect on gene expression of human primary chondrocytes in the absence of IL-1β (a) and presence of IL-1β (b). Human primary chondrocytes treated with nano-encapsulated curcumin (nano-curcumin) for 6 hours exhibited reduced mRNA levels of matrix metalloproteinase (MMP)-1, MMP-3, MMP-13, a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS5), IL-1β, TNF-α, and increased levels of CITED2 compared to that in vehicle-treated cells, while expression of collagen 2a1 (Col2a1) and aggrecan (Acan) remained unchanged. *P < 0.05, t test, n = 5/group

Topical curcumin nanoparticles localize and are effective in the infrapatellar fat pad (IPFP)

To test whether local, topical application of curcumin nanoparticles would exert increased efficacy in treating OA, we first determined whether curcumin nanoparticles could penetrate into the joint tissues following topical application to the mouse knee. Curcumin was detected in the IPFP at 3 hours following topical application as shown in Fig. 4a, but was not detected in the articular cartilage or other joint tissues, or at 6 or 24 hours following topical application (not shown), using confocal microscopy based on the auto-fluorescence of curcumin [40]. As curcumin was localized within the IPFP, we next examined the effect of curcumin nanoparticle topical treatment on the gene expression profile of pro-inflammatory mediators in the IPFP, which have been shown to have a significant impact on cartilage homeostasis and OA [4143]. As revealed by real-time PCR, the treatment suppressed mRNA expression of adipokines adipsin, leptin, adiponectin, adipo-regulatory transcription factors CCAAT/enhancer binding protein alpha (Cebpa) and peroxisome proliferator-activated receptor gamma (Pparg), and Mmp13 and Adamts5 (p < 0.05 for all, Fig. 4b).
Fig. 4

Topical application of curcumin nanoparticles on the mouse knee is localized in the infrapatellar fat pad and suppresses adipokine and adipogenesis-related gene expression. H&E staining and confocal microscopy of the infrapatellar fat pad of mouse knee joints treated with topical nano-encapsulated curcumin (Nano-C). Representative histologic images are shown (a). Relative mRNA expression of adipokines, adipogenesis-related transcription regulators, matrix metalloproteinase (MMP-13), and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS5) in the infrapatellar fat pad of curcumin nanoparticles-treated mice vs vehicle controls (b). Adp Adiponectin, Pparg peroxisome proliferator-activated receptor gamma, Cebpa CCAAT/enhancer binding protein alpha, Veh vehicle. *P < 0.05, t test, n = 3/group. Scale bar = 50 μm

Topical application of curcumin nanoparticles slows progression of OA in mice with DMM

To determine efficacy of topical application of curcumin nanoparticles on OA disease progression, we evaluated structural integrity of the articular cartilage after eight weeks of daily topical curcumin treatment beginning immediately following DMM in mice. Eight weeks after DMM, the articular cartilage in the limb with DMM in the vehicle-treated mice exhibited moderate pathological osteoarthritic change characterized by Safranin O loss and cartilage fibrillation (Fig. 5a), and an average OARSI score of 5.8 ± 2.1 (Fig. 5b). In contrast, the cartilage in the limb with DMM in mice treated with curcumin nanoparticles exhibited less Safranin O loss and cartilage fibrillation (Fig. 5a), and the mean OARSI score (1.8 ± 0.35) was significantly lower compared to vehicle-treated controls (p < 0.05, Fig. 5b). In addition, curcumin nanoparticles significantly reduced synovitis (Fig. 5c) and subchondral plate thickness (Fig. 5d) compared to vehicle-treated controls (p < 0.05 for both).
Fig. 5

Topical application of nano-encapsulated curcumin slowed the progression of OA induced by destabilization of the medial meniscus (DMM) in mice. Mice with DMM were treated daily with topical application of curcumin nanoparticles or vehicle. Mice treated topically with curcumin nanoparticles (Nano-C) exhibited improved Safranin O staining (a), lower Osteoarthritis Research Society International (OARSI) scores (b), and reduced synovitis (c), and subchondral bone plate thickness (d) at 8 weeks after surgery compared to that in vehicle control (Veh) (*p < 0.05, t test, n = 5/group). Representative histologic images are shown

Topical application of curcumin nanoparticles reduced matrix degradation markers and levels of MMP-13 and ADAMTS5 in cartilage from mice with DMM

Immunohistochemical staining showed that topical curcumin treatment strongly reduced the levels of the type II collagen cleavage epitope (Col2 3/4 M) in mice with DMM compared to vehicle-treated mice with DMM (Fig. 6a). Based on the immunostaining intensities of six randomly selected areas of the articular cartilage at 8 weeks following DMM, type II collagen cleavage was reduced to 0.58-fold in curcumin-treated animals compared to vehicle-treated controls (p < 0.05, Fig. 6a). Immunohistochemical staining similarly showed that curcumin nanoparticle treatment reduced the levels of cleaved aggrecan (NITEGE) in mice with DMM compared to vehicle-treated mice with DMM at 8 weeks (Fig. 6b). At 8 weeks after DMM, the immunostaining intensity of cleaved aggrecan in curcumin nanoparticle-treated mice with DMM was reduced to 0.68-fold compared to vehicle-treated mice (p < 0.05, Fig. 6b).
Fig. 6

Topical application of curcumin nanoparticles reduced the degradation of articular cartilage matrix and reduced the expression of matrix metalloproteinase-13 (MMP-13) and a disintegrin and metalloproteinase with thrombospondin motifs-5 (ADAMTS5). Intensity of immunohistochemical staining of type II collagen cleavage epitope (Col2-3/4 M) (a) and cleaved aggrecan (NITEGE) (b), and percentage of positive cells of immunohistochemical staining of MMP-13 (c), and of ADAMTS5 (d) in the articular cartilage of mice with destabilization of the medial meniscus (DMM) that were treated with curcumin nanoparticles (N-C) for 8 weeks following surgery were significantly reduced compared to mice with DMM treated with vehicle (Veh) (*p < 0.05, t test, n = 5/group). Scale bar = 100 μM. Representative immunohistochemical images are shown

Cartilage matrix degradation is mainly mediated by two major families of proteolytic enzymes, namely MMPs and ADAMTS [44]. In particular, MMP-13 is the most potent enzyme in cleaving type II collagen, the principal form in articular cartilage, while ADAMTS5 has been shown in mice to cleave aggrecan, the major cartilage proteoglycan [2]. We therefore examined whether reduction of MMP-13 and ADAMTS5 could underlie the chondroprotective effect of curcumin using immunohistochemical analysis.

At 8 weeks following DMM, the percentage of MMP-13-positive cells in the articular cartilage was reduced from 63 % in vehicle-treated mice to 16 % in curcumin-treated mice (p < 0.05, Fig. 6c). Similarly, curcumin reduced the percentage of ADAMTS5-positive cells from 68 % in vehicle-treated mice to 37 % (p < 0.05, Fig. 6d). These data suggest that curcumin treatment improves the integrity of the articular cartilage by preserving both collagen and aggrecan components in mice with post-traumatic OA, and that the chondroprotective effects exerted by curcumin are mediated, at least in part, by suppressing the predominant collagenase MMP-13 and predominant aggrecanase ADAMTS5.

Topical curcumin nanoparticles reduce OA-related pain

The progression of OA is accompanied by secondary clinical symptoms, most prominently pain [45, 46]. At 8 weeks following DMM, vehicle-treated mice exhibited reductions in the threshold of response to mechanical stimuli (p < 0.05, von Frey assay, Fig. 7a), distance traveled (Fig. 7b), and rearing (standing on hind limbs, Fig. 7c), compared to naïve controls (p < 0.05). Animals topically treated with curcumin nanoparticles exhibited reduced tactile hypersensitivity (p > 0.05, Fig. 7a), and increased distance traveled (p > 0.05, Fig. 7b) and rearing (p > 0.05, Fig. 7c).
Fig. 7

Topical application of curcumin nanoparticles reduces osteoarthritis-related pain symptoms. Tactile sensitivity (von Frey testing) (a), and distance traveled (b) and number of times reared (c) per 6 minutes in an open field, in mice with destabilization of the medial meniscus (DMM) treated with curcumin nanoparticles (Nano-C) at 8 weeks after DMM surgery, did not differ from naïve controls (#p > 0.05, one-way analysis of variance (ANOVA) with Tukey post-hoc test, n = 5/group), but had significant improvement compared to mice with DMM treated with vehicle (Veh) (*p < 0.05, one-way ANOVA with Tukey post-hoc test, n = 5/group)

Discussion

In this study we demonstrated the first evidence in vivo to show that oral and topical curcumin administration slows the progression of post-traumatic OA in the DMM mouse model. Specifically, we showed that oral or topical administration of curcumin immediately after DMM significantly slowed or delayed the initiation and progression of OA in mice. This was indicated by less cartilage erosion and proteoglycan loss, reduced synovitis and subchondral plate thickness, reduced degradation of type II collagen and aggrecan, and lower expression of MMP-13 and ADAMTS5 following curcumin treatment compared to vehicle controls. The preventative and therapeutic potential of curcumin is extremely valuable, given about 50 % of patients who suffer joint injuries, such as anterior cruciate ligament tears, develop OA within 10–15 years [47], and that there is no disease-modifying therapy for OA [48].

Furthermore, we provide the first evidence of a palliative effect of curcumin encapsulated in custom-made nanoparticles applied topically to an osteoarthritic joint in mice. Mice with DMM treated with curcumin nanoparticles exhibited decreased sensitivity to mechanical stimuli and increased locomotor behavior (i.e., distance traveled and rearing) compared to vehicle-treated mice, suggesting an improvement in OA-related pain. The results are consistent with a recently randomized, double-blind, placebo-controlled trial, in which patients with OA receiving a curcuminoid had significantly lower scores on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Lequesne’s pain functional index than patients receiving a placebo [23].

There is currently no cure for OA or a therapeutic agent with proven evidence to slow or halt the progression of OA [49]. Treatments used to temporarily relieve pain in OA, such as NSAIDs, may also cause severe gastrointestinal, renal, and cardiovascular side effects after long-term use [4951]. In addition, patients experiencing pain relief without a concurrent improvement in the disease itself may become less conscientious about protecting their diseased joints (such as by avoiding overuse), and may unknowingly exacerbate the progression of OA. On the other hand, an OA drug that halts the progression of OA but does not relieve OA-related pain may not be effective, as patient compliance would likely be low. Upon further validation in other animal models and clinical trials, the effects of curcumin in both disease and symptom modification make it an attractive potential therapeutic agent for OA.

While the etiologic and pathogenic mechanisms for both initiation and progression of OA are not clear, inflammation, over-activated catabolic activity and oxidative stress responses are considered to be common in both processes [2, 44, 52, 53]. The effects of curcumin on attenuating inflammation, formation of reactive oxygen species, and catabolic activity have been suggested in chondrocytes in vitro [7, 1416, 18, 19], in human synovial fibroblasts and in collagen-induced arthritis in mouse models [7, 1416, 18, 19]. Furthermore, Colitti et al have shown an anti-inflammatory effect of curcumin on the gene expression of peripheral white blood cells in dogs with OA [16]. Consistent with these studies, we demonstrated that curcumin, in both the non-encapsulated (Fig. 1) and encapsulated forms (Fig. 3) exerts broad chondroprotective effects in human primary chondrocytes by suppressing the expression of genes encoding inflammatory cytokines IL-1β and TNF-α, and cartilage-degrading enzymes from the MMP family, including MMP-1, MMP-3, and MMP-13. We also demonstrated for the first time that curcumin suppresses expression of aggrecanase ADAMTS5, a key proteinase in cartilage destruction during OA that primarily cleaves the aggrecan components of the cartilage extracellular matrix [5456]. Curcumin also induces gene expression of CITED2, an MMP-repressing transcriptional regulator. We previously demonstrated that CITED2, in response to moderate mechanical loading, represses expression of MMP-1 and MMP-13 in vitro [57] and in vivo [26]. NF-kB is a key factor that triggers the expression of various genes implicated in cartilage destruction, synovial membrane inflammation, and bone resorption [58, 59]. As CITED2 may negatively regulate NF-kB activity in embryonic kidney cells [60], curcumin may exert its chondroprotective effects by suppressing NF-kB activity by upregulating CITED2.

It has been reported that curcumin is barely soluble in water and poor absorption is attained from the epithelial cells in the gastrointestinal tract. Rats given an oral dose of curcumin excreted 75 % in the feces unchanged, with less than 0.02 % recovered from the liver, kidney, and body fat [61]. However, several studies analyzing plasma levels of curcumin or its metabolites have detected curcumin, although only small amounts, following relatively high doses of oral administration in humans [62, 63]. In this study, we demonstrated that oral administration of curcumin exerted efficacy in slowing the progression of post-traumatic OA. However, a palliative effect was not observed in mice with OA induced by DMM when curcumin was administrated orally in this study. The data suggest orally delivered curcumin is unlikely to reach biologically/pharmacologically active concentrations in the serum, synovial fluid, or joint tissues, that are sufficient to mitigate OA-related pain [4]. Together, our observation further indicates that relieving pain and its symptoms may require higher levels of curcumin compared to those required for disease modification.

As topical administration is a patient-friendly drug delivery method in OA treatment, we examined the efficacy of topical administration of nanoparticles encapsulating curcumin in OA disease modification and symptom improvement in mice with OA induced by DMM. Topical application of curcumin nanoparticles was efficacious not only in OA disease modification (Fig. 5), but also in relieving OA-related pain (Fig. 7). The data indicate that the topical application of curcumin encapsulated within nanoparticles preserves the chondroprotective activity of curcumin, and may increase its bioavailability.

Pathological changes in DMM-induced OA, including cartilage destruction, synovitis, and subchondral bone thickening, are observed in human OA [32]. Our study shows that curcumin treatment via oral (Fig. 2) or topical administration (Fig. 5) significantly improved OA-related pathological changes in the synovium and subchondral bone, indicating that curcumin has comprehensive potential for the treatment of joint tissues in OA [2].

The IPFP is an adipose tissue located within the knee joint synovial capsule, which may contribute to low-grade inflammation and cartilage degeneration through the secretion of adipokines and pro-inflammatory mediators into the synovial joint [64, 65]. In this study, we demonstrated that topically applied curcumin was largely localized in the infrapatellar fat pad (Fig. 4a). We further demonstrated that this treatment led to reduced expression of adipokines and pro-inflammatory mediators in the fat pad (Fig. 4b). These data suggest curcumin may slow the disease progression in OA, at least in part, by mitigating the pro-inflammatory mediating effect of the IPFP on cartilage and articular joints.

In this study, we provide the first evidence to demonstrate the efficacy of curcumin in OA disease and symptom modification using a post-traumatic OA mouse model. In addition to traumatic joint injuries, other conditions such as mechanical overuse and aging are risk factors for OA [66, 67]. Evaluating the efficacy of curcumin in other relevant OA models such as overuse-induced OA and spontaneous OA, which represents age-related OA, will be of interest.

Conclusions

Using a post-traumatic OA mouse model, we provide the first evidence that curcumin has significant efficacy in slowing OA disease progression and a substantial effect on pain relief. Curcumin may exert its efficacy by regulating a broad spectrum of molecules including predominant proteinases in cartilage breakdown such as collagenase MMP-13, and aggrecanase ADAMTS5 in chondrocytes. The chondroprotective effects of curcumin, when administered topically, act through, at least in part, the suppression of relevant adipokines and other pro-inflammatory mediators that are critical for cartilage homeostasis in the infrapatellar fat pad.

Abbreviations

ADAMTS, a disintegrin and metalloproteinase with thrombospondin motifs; ANOVA, analysis of variance; Cebpa, CCAAT/enhancer binding protein alpha; CITED2, Cbp/p300 interacting transactivator with ED-rich tail 2; Col2a1, collagen 2a1; COX-2, cyclooxygenase-2; DMEM, Dulbecco’s modified Eagle’s medium; DMM, destabilization of the medial meniscus; H&E, hematoxylin and eosin; IL-1β, interleukin-1 beta; IPFP, infrapatellar fat pad; MMP, matrix metalloproteinase; MMTL, medial meniscotibial ligament; NF-kB, nuclear factor kappa B; NSAID, non-steroidal anti-inflammatory drug; OA, osteoarthritis; OARSI, Osteoarthritis Research Society International; PBS, phosphate-buffered saline; PGE2, prostaglandin E2; Pparg, peroxisome proliferator-activated receptor gamma; TMOS, tetra-methyl-orthosilicate; TNF-α, tumor necrosis factor-alpha.

Declarations

Acknowledgements

This study was supported by NIH Grant R01AR050968 (HBS), the Arthritis Foundation (HBS), NIH Grant P01 HL110900 (JMF), and a sponsored research grant from NanoBiomed. Inc. (JMF, MN).

Authors’ contributions

ZZ and DJL contributed to experimental design, animal surgery, curcumin administration, histological staining and analysis and pain assessment studies, and drafted the manuscript. LX contributed to the animal surgery, curcumin administration, and revising the manuscript. ZH carried out the in vitro studies and participated in revising the manuscript. AW contributed to histological staining and revising the manuscript. MN contributed to producing the curcumin nanoparticles and revising the manuscript. SJK contributed to the acquisition of human specimens and revising the manuscript. DMH contributed to acquisition of human specimens, experimental design, and revising the manuscript. JAH contributed to experimental design and revising the manuscript. NJC contributed to conception of the study and revising the manuscript. JF contributed to conception of the study and revising the manuscript. HBS contributed to conception of the study and experimental design, analyzed the data, and finalized the manuscript. All authors have read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests with the exception of JMF and MN who are partially funded through NanoBiomed. Inc.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Orthopaedic Surgery, Albert Einstein College of Medicine
(2)
Department of Radiation Oncology, Albert Einstein College of Medicine
(3)
China-Japan Union Hospital of Jilin University
(4)
Department of Physiology & Biophysics, Albert Einstein College of Medicine
(5)
Department of Medicine, Albert Einstein College of Medicine

References

  1. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58(1):26–35.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. 2012;64(6):1697–707.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Le Graverand-Gastineau MP. Disease modifying osteoarthritis drugs: facing development challenges and choosing molecular targets. Curr Drug Targets. 2010;11(5):528–35.View ArticlePubMedGoogle Scholar
  4. Henrotin Y, Priem F, Mobasheri A. Curcumin: a new paradigm and therapeutic opportunity for the treatment of osteoarthritis: curcumin for osteoarthritis management. Springerplus. 2013;2(1):56.View ArticlePubMedPubMed CentralGoogle Scholar
  5. Asher GN, Spelman K. Clinical utility of curcumin extract. Altern Ther Health Med. 2013;19(2):20–2.PubMedGoogle Scholar
  6. Goel A, Boland CR, Chauhan DP. Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett. 2001;172(2):111–8.View ArticlePubMedGoogle Scholar
  7. Mathy-Hartert M, Jacquemond-Collet I, Priem F, Sanchez C, Lambert C, Henrotin Y. Curcumin inhibits pro-inflammatory mediators and metalloproteinase-3 production by chondrocytes. Inflamm Res. 2009;58(12):899–908.View ArticlePubMedGoogle Scholar
  8. Henrotin Y, Clutterbuck AL, Allaway D, Lodwig EM, Harris P, Mathy-Hartert M, et al. Biological actions of curcumin on articular chondrocytes. Osteoarthritis Cartilage. 2010;18(2):141–9.View ArticlePubMedGoogle Scholar
  9. Clutterbuck AL, Mobasheri A, Shakibaei M, Allaway D, Harris P. Interleukin-1beta-induced extracellular matrix degradation and glycosaminoglycan release is inhibited by curcumin in an explant model of cartilage inflammation. Ann NY Acad Sci. 2009;1171:428–35.View ArticlePubMedGoogle Scholar
  10. Shakibaei M, Mobasheri A, Buhrmann C. Curcumin synergizes with resveratrol to stimulate the MAPK signaling pathway in human articular chondrocytes in vitro. Genes Nutr. 2011;6(2):171–9.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Csaki C, Mobasheri A, Shakibaei M. Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: inhibition of IL-1beta-induced NF-kappaB-mediated inflammation and apoptosis. Arthritis Res Ther. 2009;11(6):R165.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Sreejayan N, Rao MN. Free radical scavenging activity of curcuminoids. Arzneimittelforschung. 1996;46(2):169–71.PubMedGoogle Scholar
  13. Sreejayan, Rao MN. Nitric oxide scavenging by curcuminoids. J Pharm Pharmacol. 1997;49(1):105–7.View ArticlePubMedGoogle Scholar
  14. Liacini A, Sylvester J, Li WQ, Zafarullah M. Inhibition of interleukin-1-stimulated MAP kinases, activating protein-1 (AP-1) and nuclear factor kappa B (NF-kappa B) transcription factors down-regulates matrix metalloproteinase gene expression in articular chondrocytes. Matrix Biol. 2002;21(3):251–62.View ArticlePubMedGoogle Scholar
  15. Shakibaei M, John T, Schulze-Tanzil G, Lehmann I, Mobasheri A. Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: implications for the treatment of osteoarthritis. Biochem Pharmacol. 2007;73(9):1434–45.View ArticlePubMedGoogle Scholar
  16. Schulze-Tanzil G, Mobasheri A, Sendzik J, John T, Shakibaei M. Effects of curcumin (diferuloylmethane) on nuclear factor kappaB signaling in interleukin-1beta-stimulated chondrocytes. Ann NY Acad Sci. 2004;1030:578–86.View ArticlePubMedGoogle Scholar
  17. Clutterbuck AL, Allaway D, Harris P, Mobasheri A. Curcumin reduces prostaglandin E2, matrix metalloproteinase-3 and proteoglycan release in the secretome of interleukin 1beta-treated articular cartilage. F1000Res. 2013;2:147.PubMedPubMed CentralGoogle Scholar
  18. Moon DO, Kim MO, Choi YH, Park YM, Kim GY. Curcumin attenuates inflammatory response in IL-1beta-induced human synovial fibroblasts and collagen-induced arthritis in mouse model. Int Immunopharmacol. 2010;10(5):605–10.View ArticlePubMedGoogle Scholar
  19. Colitti M, Gaspardo B, Della Pria A, Scaini C, Stefanon B. Transcriptome modification of white blood cells after dietary administration of curcumin and non-steroidal anti-inflammatory drug in osteoarthritic affected dogs. Vet Immunol Immunopathol. 2012;147(3-4):136–46.View ArticlePubMedGoogle Scholar
  20. Peddada KV, Peddada KV, Shukla SK, Mishra A, Verma V. Role of curcumin in common musculoskeletal disorders: a review of current laboratory, translational, and clinical data. Orthop Surg. 2015;7(3):222–31.View ArticlePubMedGoogle Scholar
  21. Comblain F, Serisier S, Barthelemy N, Balligand M, Henrotin Y. Review of dietary supplements for the management of osteoarthritis in dogs in studies from 2004 to 2014. J Vet Pharmacol Ther. 2016;39(1):1–15.View ArticlePubMedGoogle Scholar
  22. Nakagawa Y, Mukai S, Yamada S, Matsuoka M, Tarumi E, Hashimoto T, et al. Short-term effects of highly-bioavailable curcumin for treating knee osteoarthritis: a randomized, double-blind, placebo-controlled prospective study. J Orthop Sci. 2014;19(6):933–9.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Panahi Y, Rahimnia AR, Sharafi M, Alishiri G, Saburi A, Sahebkar A. Curcuminoid treatment for knee osteoarthritis: a randomized double-blind placebo-controlled trial. Phytother Res. 2014;28(11):1625–31.View ArticlePubMedGoogle Scholar
  24. Kuptniratsaikul V, Dajpratham P, Taechaarpornkul W, Buntragulpoontawee M, Lukkanapichonchut P, Chootip C, et al. Efficacy and safety of Curcuma domestica extracts compared with ibuprofen in patients with knee osteoarthritis: a multicenter study. Clin Interv Aging. 2014;9:451–8.View ArticlePubMedPubMed CentralGoogle Scholar
  25. He Z, Leong DJ, Zhuo Z, Majeska RJ, Cardoso L, Spray DC, Goldring MB, Cobelli NJ, Sun HB. Strain-induced mechanotransduction through primary cilia, extracellular ATP, purinergic calcium signaling, and ERK1/2 transactivates CITED2 and downregulates MMP-1 and MMP-13 gene expression in chondrocytes. Osteoarthritis Cartilage. 2015;24(5):892–901.Google Scholar
  26. Leong DJ, Li YH, Gu XI, Sun L, Zhou Z, Nasser P, et al. Physiological loading of joints prevents cartilage degradation through CITED2. FASEB J. 2011;25(1):182–91.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Friedman AJ, Han G, Navati MS, Chacko M, Gunther L, Alfieri A, et al. Sustained release nitric oxide releasing nanoparticles: characterization of a novel delivery platform based on nitrite containing hydrogel/glass composites. Nitric Oxide. 2008;19(1):12–20.View ArticlePubMedGoogle Scholar
  28. Han G, Martinez LR, Mihu MR, Friedman AJ, Friedman JM, Nosanchuk JD. Nitric oxide releasing nanoparticles are therapeutic for Staphylococcus aureus abscesses in a murine model of infection. PLoS One. 2009;4(11):e7804.View ArticlePubMedPubMed CentralGoogle Scholar
  29. Cabrales P, Han G, Roche C, Nacharaju P, Friedman AJ, Friedman JM. Sustained release nitric oxide from long-lived circulating nanoparticles. Free Radic Biol Med. 2010;49(4):530–8.View ArticlePubMedPubMed CentralGoogle Scholar
  30. Tar M, Cabrales P, Navati M, Adler B, Nacharaju P, Friedman AJ, et al. Topically applied NO-releasing nanoparticles can increase intracorporal pressure and elicit spontaneous erections in a rat model of radical prostatectomy. J Sex Med. 2014;11(12):2903–14.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Krausz AE, Adler BL, Cabral V, Navati M, Doerner J, Charafeddine RA, et al. Curcumin-encapsulated nanoparticles as innovative antimicrobial and wound healing agent. Nanomedicine. 2015;11(1):195–206.PubMedPubMed CentralGoogle Scholar
  32. Glasson SS, Blanchet TJ, Morris EA. The surgical destabilization of the medial meniscus (DMM) model of osteoarthritis in the 129/SvEv mouse. Osteoarthritis Cartilage. 2007;15(9):1061–9.View ArticlePubMedGoogle Scholar
  33. Glasson SS, Chambers MG, Van Den Berg WB, Little CB. The OARSI histopathology initiative - recommendations for histological assessments of osteoarthritis in the mouse. Osteoarthritis Cartilage. 2010;18 Suppl 3:S17–23.View ArticlePubMedGoogle Scholar
  34. Lewis JS, Hembree WC, Furman BD, Tippets L, Cattel D, Huebner JL, et al. Acute joint pathology and synovial inflammation is associated with increased intra-articular fracture severity in the mouse knee. Osteoarthritis Cartilage. 2011;19(7):864–73.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Milz S, Putz R. Quantitative morphology of the subchondral plate of the tibial plateau. J Anat. 1994;185(Pt 1):103–10.PubMedPubMed CentralGoogle Scholar
  36. Nguyen DH, Zhou T, Shu J, Mao JH.  Quantifying chromogen intensity in immunohistochemistry via reciprocal intensity. Cancer InCytes. 2013;2(1):e.Google Scholar
  37. Leong DJ, Choudhury M, Hanstein R, Hirsh DM, Kim SJ, Majeska RJ, et al. Green tea polyphenol treatment is chondroprotective, anti-inflammatory and palliative in a mouse post-traumatic osteoarthritis model. Arthritis Res Ther. 2014;16(6):508.View ArticlePubMedPubMed CentralGoogle Scholar
  38. Bailey KR, Crawley JN. Anxiety-Related Behaviors in Mice. In: Buccafusco JJ, editor. Methods of Behavior Analysis in Neuroscience. 2nd edition. Boca Raton (FL): CRC Press/Taylor & Francis; 2009. Chapter 5.Google Scholar
  39. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807–18.View ArticlePubMedGoogle Scholar
  40. Kunwar A, Barik A, Mishra B, Rathinasamy K, Pandey R, Priyadarsini KI. Quantitative cellular uptake, localization and cytotoxicity of curcumin in normal and tumor cells. Biochim Biophys Acta. 2008;1780(4):673–9.View ArticlePubMedGoogle Scholar
  41. Santangelo K, Radakovich L, Fouts J, Foster MT. Pathophysiology of obesity on knee joint homeostasis: contributions of the infrapatellar fat pad. Horm Mol Biol Clin Investig. 2016. doi:10.1515/hmbci-2015-0067.PubMedGoogle Scholar
  42. Richter M, Trzeciak T, Owecki M, Pucher A, Kaczmarczyk J. The role of adipocytokines in the pathogenesis of knee joint osteoarthritis. Int Orthop. 2015;39(6):1211–7.View ArticlePubMedGoogle Scholar
  43. Conde J, Scotece M, Lopez V, Abella V, Hermida M, Pino J, et al. Differential expression of adipokines in infrapatellar fat pad (IPFP) and synovium of osteoarthritis patients and healthy individuals. Ann Rheum Dis. 2014;73(3):631–3.View ArticlePubMedGoogle Scholar
  44. Goldring MB, Marcu KB. Cartilage homeostasis in health and rheumatic diseases. Arthritis Res Ther. 2009;11(3):224.View ArticlePubMedPubMed CentralGoogle Scholar
  45. Felson DT. Developments in the clinical understanding of osteoarthritis. Arthritis Res Ther. 2009;11(1):203.View ArticlePubMedPubMed CentralGoogle Scholar
  46. Miller RE, Tran PB, Das R, Ghoreishi-Haack N, Ren D, Miller RJ, et al. CCR2 chemokine receptor signaling mediates pain in experimental osteoarthritis. Proc Natl Acad Sci U S A. 2012;109(50):20602–7.View ArticlePubMedPubMed CentralGoogle Scholar
  47. Wong JM, Khan T, Jayadev CS, Khan W, Johnstone D. Anterior cruciate ligament rupture and osteoarthritis progression. Open Orthop J. 2012;6:295–300.View ArticlePubMedPubMed CentralGoogle Scholar
  48. Lotz MK, Kraus VB. New developments in osteoarthritis. Posttraumatic osteoarthritis: pathogenesis and pharmacological treatment options. Arthritis Res Ther. 2010;12(3):211.View ArticlePubMedPubMed CentralGoogle Scholar
  49. Cheng DS, Visco CJ. Pharmaceutical therapy for osteoarthritis. PM R. 2012;4(5 Suppl):S82–8.View ArticlePubMedGoogle Scholar
  50. O'Neil CK, Hanlon JT, Marcum ZA. Adverse effects of analgesics commonly used by older adults with osteoarthritis: focus on non-opioid and opioid analgesics. Am J Geriatr Pharmacother. 2012;10(6):331–42.View ArticlePubMedPubMed CentralGoogle Scholar
  51. Van Manen MD, Nace J, Mont MA. Management of primary knee osteoarthritis and indications for total knee arthroplasty for general practitioners. J Am Osteopath Assoc. 2012;112(11):709–15.PubMedGoogle Scholar
  52. Loeser RF. Aging processes and the development of osteoarthritis. Curr Opin Rheumatol. 2013;25(1):108–13.View ArticlePubMedPubMed CentralGoogle Scholar
  53. Sun HB. Mechanical loading, cartilage degradation, and arthritis. Ann NY Acad Sci. 2010;1211:37–50.View ArticlePubMedGoogle Scholar
  54. Larkin J, Lohr TA, Elefante L, Shearin J, Matico R, Su JL, et al. Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification. Osteoarthritis Cartilage. 2015;23(8):1254–66.View ArticlePubMedGoogle Scholar
  55. Verma P, Dalal K. ADAMTS-4 and ADAMTS-5: key enzymes in osteoarthritis. J Cell Biochem. 2011;112(12):3507–14.View ArticlePubMedGoogle Scholar
  56. Glasson SS, Askew R, Sheppard B, Carito B, Blanchet T, Ma HL, et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature. 2005;434(7033):644–8.View ArticlePubMedGoogle Scholar
  57. Yokota H, Goldring MB, Sun HB. CITED2-mediated regulation of MMP-1 and MMP-13 in human chondrocytes under flow shear. J Biol Chem. 2003;278(47):47275–80.View ArticlePubMedGoogle Scholar
  58. Rigoglou S, Papavassiliou AG. The NF-kappaB signalling pathway in osteoarthritis. Int J Biochem Cell Biol. 2013;45(11):2580–4.View ArticlePubMedGoogle Scholar
  59. Marcu KB, Otero M, Olivotto E, Borzi RM, Goldring MB. NF-kappaB signaling: multiple angles to target OA. Curr Drug Targets. 2010;11(5):599–613.View ArticlePubMedPubMed CentralGoogle Scholar
  60. Lou X, Sun S, Chen W, Zhou Y, Huang Y, Liu X, et al. Negative feedback regulation of NF-kappaB action by CITED2 in the nucleus. J Immunol. 2011;186(1):539–48.View ArticlePubMedGoogle Scholar
  61. Wahlstrom B, Blennow G. A study on the fate of curcumin in the rat. Acta Pharmacol Toxicol (Copenh). 1978;43(2):86–92.View ArticleGoogle Scholar
  62. Lao CD, Ruffin MT, Normolle D, Heath DD, Murray SI, Bailey JM, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med. 2006;6:10.View ArticlePubMedPubMed CentralGoogle Scholar
  63. Carroll RE, Benya RV, Turgeon DK, Vareed S, Neuman M, Rodriguez L, et al. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila). 2011;4(3):354–64.View ArticleGoogle Scholar
  64. Greene MA, Loeser RF. Aging-related inflammation in osteoarthritis. Osteoarthritis Cartilage. 2015;23(11):1966–71.View ArticlePubMedGoogle Scholar
  65. Conde J, Scotece M, Lopez V, Gomez R, Lago F, Pino J, et al. Adipokines: novel players in rheumatic diseases. Discov Med. 2013;15(81):73–83.PubMedGoogle Scholar
  66. Silverwood V, Blagojevic-Bucknall M, Jinks C, Jordan JL, Protheroe J, Jordan KP. Current evidence on risk factors for knee osteoarthritis in older adults: a systematic review and meta-analysis. Osteoarthritis Cartilage. 2015;23(4):507–15.View ArticlePubMedGoogle Scholar
  67. Bijlsma JW, Knahr K. Strategies for the prevention and management of osteoarthritis of the hip and knee. Best Pract Res Clin Rheumatol. 2007;21(1):59–76.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement